Conference Coverage

Consider caregiver oral health for children with bleeding disorders


 

REPORTING FROM THSNA 2018


More than one-quarter of patients (27%) reported not having a current dentist and 15% reported specific challenges with access to dental care including burdens related to distance, insurance coverage, and finding a provider willing to treat in the setting of their medical condition. Those who were Medicaid eligible or of low socioeconomic status were significantly more likely to report dental care access issues, compared with other patients (20% vs. 9%; P = .01).

Oral screening performed by the dental hygienist demonstrated significant oral pathology: 89% of patients had plaque accumulation, 57% had white spots or decalcifications, 37% had gingivitis, and 8% had suspicious lesions suggestive of dental caries.


The researchers also found that having a caregiver with active oral disease in the past 12 months increased the odds of suspicious lesions (odds ratio, 4.34), increased the odds of gingivitis (OR, 3.80), and decreased the odds of the patients’ brushing their teeth at least twice per day (OR, 0.17).

“Hopefully, if we can target those high-risk patients in clinic, we could reduce costs, the number of bleeds, the number of products and factor used, and potentially even morbidity in the future,” Ms. Hastie said.

She acknowledged certain limitations of the study, including its single-center design and the fact that a dental hygienist performed the majority of evaluations. She reported having no financial disclosures.

Pages

Recommended Reading

Researchers seek better understanding of von Willebrand disease
MDedge Hematology and Oncology
Two scoring systems helpful in diagnosing heparin-induced thrombocytopenia
MDedge Hematology and Oncology
FDA approves new drug for thrombocytopenia
MDedge Hematology and Oncology
Experts offer guidance on use of emicizumab
MDedge Hematology and Oncology
Time to scrap LMWH for prevention of placenta-mediated pregnancy complications?
MDedge Hematology and Oncology
Fostamatinib produces responses in ITP
MDedge Hematology and Oncology
Fostamatinib approved to treat adults with chronic ITP
MDedge Hematology and Oncology
Emicizumab receives breakthrough designation
MDedge Hematology and Oncology
FDA expands approved use of product for VWD
MDedge Hematology and Oncology
Team modifies platelets to improve coagulation
MDedge Hematology and Oncology